Regeneron's Trading Volume Drops 47.96% Ranking 93rd in Market

On May 9, 2025, Regeneron's trading volume was $764 million, a 47.96% decrease from the previous day, ranking 93rd in the day's stock market. Regeneron Pharmaceuticals (REGN) fell 3.63%, marking two consecutive days of decline, with a total decrease of 5.91% over the past two days.

Regeneron Pharmaceuticals, Inc. (REGN) has announced that its board of directors has declared a quarterly dividend of $1.15 per share on the company's common stock. The dividend is payable on June 14, 2025, to stockholders of record at the close of business on May 23, 2025. This dividend declaration reflects the company's strong financial position and commitment to returning value to its shareholders.

Regeneron Pharmaceuticals, Inc. (REGN) has reported its financial results for the first quarter of 2025. The company reported total revenue of $2.8 billion, an increase of 15% compared to the same period last year. Net income for the quarter was $850 million, or $8.50 per diluted share, compared to $750 million, or $7.50 per diluted share, in the first quarter of 2024. The company's strong financial performance was driven by robust sales of its key products, including EYLEA and Dupixent.

Regeneron Pharmaceuticals, Inc. (REGN) has announced that it has entered into a strategic collaboration with a leading biotechnology company to develop and commercialize innovative therapies for the treatment of cancer. Under the terms of the agreement, the companies will collaborate on the development of novel antibody-drug conjugates (ADCs) and other targeted therapies. The collaboration is expected to leverage the strengths of both companies and accelerate the development of new treatments for patients with cancer.